GlassScriptPhysician profile
Morgan Mccoy
NPI 1922711241
$3,570.97
in general payments reported to CMS, 2019-2025
31 companies · $2,035 in 2025
The $2,035 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $582 · 2024: $954 · 2025: $2,035.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,572 · Travel and Lodging: $972 · Education: $27.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,571.85 |
| Travel and Lodging | $972.12 |
| Education | $27.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,369.79 | 2024-2025 | Interstim |
| Dendreon Pharmaceuticals LLC | $308.19 | 2024-2025 | Provenge |
| Sumitomo Pharma America, INC. | $163.50 | 2024-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $150.64 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $122.90 | 2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.06 | 2023-2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $111.36 | 2024 | Farxiga |
| Urogen Pharma, INC. | $93.01 | 2025 | |
| Lilly USA, LLC | $86.86 | 2023 | Mounjaro, Jardiance |
| Janssen Biotech, INC. | $82.00 | 2024-2025 | Erleada, Balversa, Akeega |
| Calyxo, INC. | $79.96 | 2025 | Cvac Aspiration System |
| Novo Nordisk INC | $76.66 | 2023 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $73.41 | 2025 | |
| Endo USA, INC. | $73.08 | 2024-2025 | Xiaflex |
| Caris Mpi, INC. | $71.11 | 2025 | Mi Cancer Seek |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $64.97 | 2024 | Austedo Xr |
| Amgen INC. | $61.26 | 2023 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $55.44 | 2024-2025 | Keytruda, Lynparza |
| Abbvie INC. | $54.39 | 2023-2025 | |
| C. R. Bard, INC. & Subsidiaries | $52.88 | 2025 | Bard Urinary Drainage Bag |
| Glaxosmithkline, LLC. | $37.59 | 2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $34.71 | 2024 | Veozah |
| Teleflex LLC | $34.65 | 2025 | Barrigel |
| Photocure INC | $31.36 | 2025 | Cysview |
| Exact Sciences Corporation | $30.30 | 2023 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $29.42 | 2023 | Nexletol |
| Sun Pharmaceutical Industries INC. | $23.57 | 2025 | |
| Myriad Genetic Laboratories, INC. | $22.80 | 2025 | Prolaris |
| Tempus Ai, INC | $20.47 | 2025 | Xt Cdx |
| Ferring Pharmaceuticals INC. | $19.68 | 2025 | Adstiladrin |
| Olympus America INC. | $15.95 | 2025 | Itind System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Mccoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.